Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO DOC! event, informing about colorectal cancer, cutting-edge research, new treatment modalities, and holistic therapeutic approaches. This event will take place on March 20, 2024, in Berlin, Germany, aligning with the Colorectal Cancer Awareness Month.

HALLO DOC! comes at a critical time as the incidence of colorectal cancer increases alarmingly, particularly among the youth, emphasizing the necessity for effective prevention, early detection, and the avoidance of recurrence. Mainz Biomed has organized this event to shed light on new diagnostic methods, the importance of a comprehensive treatment approach, and the latest advancements in colorectal cancer research.

Event Highlights:

• Expert Insights: Keynote presentations by renowned experts, including Prof. Dr. Guido Schumacher, Priv. Doz. Dr. med Annika Kurreck, Prof. Dr. Ingo Froböse, and Priv. Doz. Dr. Severin Daum, offering invaluable insights into modern colorectal cancer treatment methods, the critical role of early detection, and personalized medicine.
• Patient Perspective: A moving account by Jule Blöhmer, a young colorectal cancer survivor, aiming to inspire and inform others about the journey through diagnosis, treatment, and recovery.
• Interactive Sessions: Engaging Q&A sessions with the audience, both on-site and streaming online, facilitating a deeper understanding and discussion about colorectal cancer.
• Innovative Research: Presentation of groundbreaking studies on the role of the microbiome and molecular markers in colorectal cancer prevention and treatment, highlighting Mainz Biomed’s contributions to the field.
• Networking Opportunity: A “Get Together” session to conclude the event, allowing for personal interactions among attendees, speakers, and professionals.

Attendance:

• Time & Date: March 20, 2024, from 05:00 pm to 08:00 pm (CET)
• Location: bUM Berlin, Germany
• Online Participation: https://www.eventbrite.com/e/hallo-doc-darmkrebs-neue-behandlungsmethoden-und-therapieansatze-tickets-852062952227 
• Phone number for ticket reservations: +49 (0)152-12689355

Mainz Biomed is at the forefront of developing market-ready, molecular-genetic diagnostic solutions for life-threatening conditions. Its flagship product, ColoAlert^®, offers an accurate, non-invasive, and easy-to-use at-home screening test for colorectal cancer, marking a significant advancement in early detection and prevention strategies.

Guido Baechler, Chief Executive Officer of Mainz Biomed, commented, “As we witness a disturbing trend over the past two decades – a rise in colorectal cancer cases among younger populations – it’s imperative to focus on innovative solutions and holistic approaches to combat this disease. The HALLO DOC! event represents our commitment to advancing the dialogue on prevention, early detection, and treatment, featuring insights from some of the most esteemed professionals in the field.”

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information.

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About ColoAlert^®
ColoAlert^®, Mainz Biomed’s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert^® detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Dollinger et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert^® will be evaluated in the FDA-registration trial ‘ReconAAsense.’ Once approved in the US, the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

About Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert^® should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.

About Mainz Biomed N.V.  
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert^®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert^® is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit mainzbiomed.com.   

For media inquiries

In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

In the U.S.:
Blueprint Life Science Group
Hershel Berry
+1 415 505 3749
hberry@bplifescience.com

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on April 7, 2023. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.